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D
iabetes mellitus is associated with increased fracture risk despite preservation of bone mineral density and reduced bone turnover (1) (2) (3) . Proposed mechanisms include a shift of mesenchymal stem cell differentiation toward adipocytes rather than osteoblasts (4), impaired mineralization due to altered osteoclast differentiation (5-7), osteoblast and osteoclast dysfunction from reduced activity of the insulin receptor substrate (8, 9) , elevated sclerostin levels (10) , reduced circulating IGF-1 concentrations (10, 11) , the effect of chronic inflammation, and the pathogenic effect of advanced glycation end products (AGEs) on bone (1, 2, 12) . AGEs are nonenzymatic chemical modifications of proteins by aldose sugars (1, 2, 13, 14) that are associated with macrovascular and microvascular complications of diabetes (13) (14) (15) (16) (17) (18) . AGEs generate oxidative stress and interact with the receptor for advanced glycation end products (RAGE) (13, 14, (16) (17) (18) , a transmembrane receptor that activates cell signaling pathways such as the proinflammatory nuclear factor k-b (14, (17) (18) (19) .
Of the many AGEs detected in tissue, pentosidine and carboxymethyllysine (CML) are the most prominent and best characterized (2, 13, 18) . Reactive intermediate products, including methylglyoxal and glyoxal, are formed during glycation (13, 18) , but there have been few studies examining the significance of these compounds. Endogenous secretory RAGE (esRAGE) is an isoform of RAGE that lacks the transmembrane and signaling domain and is believed to act as a decoy receptor, binding AGEs and reducing the AGE-RAGE interaction and activity of related intracellular signaling pathways (20) . Previous studies have reported variable associations between diabetes, AGEs, bone turnover, and fracture risk in humans. Bone turnover markers have been reported as unrelated to, or positively associated with, serum pentosidine (21, 22) and negatively associated with CML (23) . There is evidence of a positive association between serum pentosidine and fracture risk in cohorts of people with type 1 and type 2 diabetes (21, 22, 24, 25) , and a study in the general population demonstrated a positive linear association between CML and hip fracture risk in a cohort of older men and women that was attenuated following adjustment for covariates (26) . Low esRAGE levels have been shown to be a risk factor for vertebral fractures in patients with type 2 diabetes (27) , and higher esRAGE to pentosidine ratios have been associated with a decreased risk of fragility fractures independent of bone mineral density (BMD) (25) .
Osteoporosis is increasingly recognized as a major contributor to morbidity in older men who are also at increased risk of diabetes (28) . The relationship between diabetic advanced glycation with both bone physiology and fracture risk remains unclear, particularly in the general population of older men who are at risk for osteoporosis. In this study, we examine the associations between CML, methylglyoxal, glyoxal, and esRAGE with diabetes, bone turnover, and hip fracture risk in a population of older men. We hypothesized that, in older men with or without diabetes, circulating AGEs and esRAGE are associated with bone turnover and fracture risk.
Subjects and Methods

Study population
The Health in Men Study is a cohort of community-dwelling men from Perth, Western Australia (29) . Men aged $65 years were randomly selected from the electoral roll and invited to participate in the study. There were 12,203 who participated in wave 1 from 1996 to 1999, and 4248 participated in wave 2 (W2) from 2001 to 2004, which comprised reassessment, including repeat blood sampling. Participants were predominantly white. The University of Western Australia Human Research Ethics Committee approved the study, and all men gave written informed consent.
Assessment of medical comorbidities
Medical data collected at W2 were used to identify men with a history of prostate cancer, osteoporosis or bone fracture, and Paget disease. Medication data were analyzed to identify men receiving androgens or antiandrogen therapy, bisphosphonates, or glucocorticoids. Men diagnosed with diabetes, reporting the use of blood glucose-lowering medication, or with fasting or nonfasting blood glucose at W2 of $7.0 mmol/L or $11.1 mmol/L, respectively, were considered to have diabetes (30, 31) .
Ascertainment of incident hip fracture
Further assessment of morbidity was performed via the Western Australian Data Linkage System (WADLS), which provides electronic linkage to records from death, hospital, and cancer registries and captures admissions to all public and private hospitals in Western Australia (32 
Laboratory assays
Blood samples were collected between 0800 and 1030 hours at W2. Aliquots of plasma and serum were prepared immediately following phlebotomy and stored at 280°C until assayed. Bone turnover markers, including collagen type 1 C-terminal cross-linked telopeptide, N-terminal propeptide of type 1 collagen (P1NP), undercarboxylated osteocalcin (ucOC), and total osteocalcin (TOC), were assayed using immunoassay as previously reported (30, 33) . The interassay coefficients of variation (CVs) for the bone turnover markers were 3.7% and 2.9% at 18 and 89 mg/L TOC, 4.0% and 5.7% at 28 and 191 mg/L P1NP, and 4.1% and 3.8% at 0.31 and 0.71 mg/L C-terminal cross-linked telopeptide, respectively. Plasma CML was measured in 3011 men, and methylglyoxal, glyoxal, and esRAGE were measured in a random subset of these men. CML was assayed using a validated indirect ELISA (25) .
Interassay CV for CML was 7.9%. esRAGE was assayed using a commercial ELISA (Quantikine; R&D Systems). Interassay CV for esRAGE was 8.2%. Glyoxal and methylglyoxal were determined as published previously (34) . In detail, 20 mL of 55% trichloroacetic acid was added to 180 mL of plasma. The sample was vortexed and incubated at room temperature for 20 minutes to allow for protein precipitation to occur and glyoxal and methylglyoxal to be released. The sample was centrifuged at room temperature for 20 minutes at 15,000 rpm in an Eppendorf mini centrifuge. Following centrifugation, 150 mL of the supernatant was transferred into a labeled thermoresistant plastic vial containing 70 mL of 2.5 mM sodium phosphate buffer (pH 9.5) and 35 mL of 5 mM diethylenetriaminepentaacetic acid. Finally, 5 mL of a 3-mM 5,6-diamino-2,4-hydroxypyrimidine sulfate solution was added and the sample incubated at 60°C for 2 hours. After incubation, 14.5 mL of concentrated HCl (37%) was added to adjust the pH to 4.0. Then, 50 mL of the sample was injected into the chromatographic system. A Dionex TM HPLC system (Thermo Fisher Scientific) equipped with a P680 HPLC pump, an ASI-100 automated sample injector, a column oven (thermostated column compartment TCC-100) equipped with a phenyl-hexyl column at 40°C, a PDA ultraviolet/visible detector, and an RF-2000 fluorescent detector were used. The Chromeleon 6.7 Chromatography Data System from Dionex TM (Thermo Fisher Scientific) was used to control the instrument (pump, column oven, and detectors), acquire data, and quantify the peak areas. A composition of formic acid (0.01%)/water (solvent A) and methanol (solvent B) with gradient elution system at a flow rate of 0.75 mL/min was used as a mobile phase. Lumazine (the reaction product of glyoxal) and methyllumazine (the reaction product of methylglyoxal) were quantitated via fluorescence detection (excitation/emission 330/460 nm) using a standard curve with lumazine and methyllumazine standards. The interassay CV was 1.8% for glyoxal and 0.9% for methylglyoxal.
Statistical analysis
Baseline characteristics are shown as mean and SD or numbers and percentages. Linear regression analyses were used to examine the association of CML, methylglyoxal, glyoxal, and esRAGE with fasting glucose and bone turnover markers. As the distribution of CML was skewed to the right, analyses were also performed using ln(CML). Cox proportional hazards regression was performed to assess the association of CML with incident hip fracture. Models were adjusted for variables that might possibly confound the results, including age, smoking, hypertension, dyslipidemia, prevalent cardiovascular disease, prevalent diabetes, frailty, body mass index (BMI)/waist, creatinine, and vitamin D. A two-tailed P value ,0.05 was considered significant.
Results
Participant characteristics
Demographic and clinical characteristics are summarized in Table 1 . Excluding 24 men with Paget disease of the bone, 127 with known osteoporosis, 192 with previous bone fracture, 11 receiving bisphosphonates, 60 receiving glucocorticoids, and 212 on warfarin, there were 3384 men with data available for analysis. Their mean age was 76.8 years, and their mean BMI was 26.5 kg/m 2 . The 502 men with diabetes were more likely to have hypertension, frailty, and cardiovascular disease than the 2882 men without diabetes.
The men with diabetes also had a higher BMI and waist circumference, higher serum creatinine, a lower serum vitamin D, and lower bone turnover. Plasma CML was measured in 3011 men, methylglyoxal and glyoxal were measured in 766 men, and esRAGE was measured in 748 men. Plasma CML, methylglyoxal, glyoxal, and esRAGE were similar in men without and with diabetes. When men with diabetes from our study cohort were stratified according to duration of diabetes and use of insulin, there were no significant differences in the distributions of circulating AGEs and esRAGE for men with diabetes duration ,5 years and $5 years or for those on oral therapy and those on insulin (35).
CML, esRAGE, and fasting serum glucose
Associations between AGEs, esRAGE, and fasting serum glucose are summarized in Table 2 . In the 2676 men who were fasting at the time of blood sampling and after adjusting for potential confounders, plasma CML was positively associated with fasting serum glucose (fully adjusted analysis: 0.06-SD increase in CML per 1-mmol/L increase in fasting serum glucose, P , 0.001). A similar result was seen with ln(CML). esRAGE was inversely associated with fasting serum glucose (fully adjusted analysis: 0.08-SD decrease in esRAGE per 1-mmol/L increase in fasting serum glucose, P = 0.045).
esRAGE and bone turnover markers
Associations between AGEs, esRAGE, and bone turnover markers are summarized in Tables 3 through 5. In the multivariable analysis, esRAGE was independently associated with bone turnover, particularly bone formation (per 1-SD increase esRAGE: 0.17-SD increase in P1NP, P , 0.001; 0.11-SD increase in ucOC, P = 0.008; 0.16-SD increase in TOC, P , 0.001) ( Table 3) . When analyzed according diabetes status, the association between esRAGE and bone turnover markers was more apparent in men with diabetes compared with men without (per 1-SD increase in esRAGE: 0.12-SD increase in P1NP in men without diabetes, P = 0.017 and 0.36-SD increase in P1NP in men with diabetes, P = 0.007; 0.08-SD increase in TOC in men without diabetes, P = 0.170 and 0.24-SD increase in men with diabetes, P = 0.012) ( Tables 4 and 5 ).
CML and hip fracture risk
In the 3011 men with CML concentrations, 106 incident hip fractures occurred during follow-up. The cumulative risk of incident hip fracture is shown in Fig. 1 , stratified according to quartiles of CML. Men with CML in the third quartile had the lowest cumulative risk. Cox proportional hazards regression models are shown in Table 6 . In the fully adjusted analysis, compared with men with CML in the lowest (reference) quartile, men in the third quartile had a lower incidence of hip fracture (hazard ratio, 0.49; 95% CI, 0.24 to 0.99; P = 0.045).
Discussion
This study demonstrates that, in older men, fasting serum glucose correlated with serum CML and inversely with the decoy receptor esRAGE. esRAGE was independently associated with markers of bone formation. Furthermore, there was evidence of a nonlinear association between CML and incidence of hip fracture.
The positive association between fasting serum glucose and CML is consistent with previous evidence that chronic hyperglycemia accelerates the process of nonenzymatic glycation (12, 18) . Several studies have examined the relationship between glycemia and AGEs with varying results. Makita et al. (36) demonstrated elevated AGEs in arterial wall collagen samples obtained at autopsy and in the circulation of living subjects with diabetes compared with those without diabetes. Miura et al. (15) found no correlation between serum AGEs and fasting plasma glucose but did report a significant correlation between both serum levels of CML Variables of interest: n 5 number of men from the study population after exclusions, in whom that result is available. Men diagnosed with diabetes, reporting use of glucose-lowering medication, or with fasting glucose at W2 of $7 mmol/L or nonfasting $11.1 mmol/L were considered to have diabetes. Data are shown as mean 6 SD or n (%). P value is for comparison between men without and with diabetes.
Abbreviation: CTX, C-terminal cross-linked telopeptide. (21) showed that serum pentosidine did not correlate with HbA 1c and that pentosidine concentrations were similar in persons with and without diabetes. We found no significant difference in the concentrations of AGEs and esRAGE in older men with diabetes compared with those without diabetes. Serum CML levels were higher and esRAGE was lower in men with diabetes compared with other men, but these differences were not significant, perhaps reflecting the large interindividual variation resulting in overlapping distributions of these analytes in the two groups. By contrast, serum CML was positively associated with fasting glucose, consistent with mediation of circulating AGEs by glycemia. Neither of the intermediates glyoxal or methylglyoxal was associated with fasting serum glucose. The robust association we demonstrated between serum CML and fasting glucose may be accounted for by our large cohort of men predominantly without diabetes and therefore with stable fasting glucose levels that were not influenced by treatments such as insulin. The negative association between esRAGE and fasting serum glucose would be consistent with hyperglycemia suppressing esRAGE. Given the proposed role of esRAGE as a decoy receptor acting to reduce the pathogenic effects of the AGE-RAGE interaction (20) , a lower circulating esRAGE concentration in the setting of hyperglycemia would be expected to increase the deleterious effects of AGEs.
AGEs have multiple biological effects on bone metabolism that should result in increased bone fragility. In vitro studies have demonstrated that they affect multiple cell lines with inhibition of osteoblast proliferation and induction of osteoblast apoptosis (37, 38) , as well as decreasing osteoclast-induced bone resorption and osteoclast differentiation (39) . AGEs have been shown to increase the expression of sclerostin and decrease the expression of receptor activator of nuclear factor kappa-B ligand in osteocytelike cells (40) . Overall, these effects suggest that the pathogenesis of reduced bone turnover in diabetes may be due to accumulation of AGEs (2) . Furthermore, AGEs alter the biomechanical properties of bone tissue via nonenzymatic cross-linking of collagen, resulting in impaired bone quality and increased fragility (3, 41) .
We demonstrated that esRAGE is positively correlated with the bone formation markers P1NP, ucOC, and TOC with a stronger association in men with diabetes compared with men without diabetes. Conversely, lower circulating esRAGE was associated with reduced bone formation. We postulate that lower circulating esRAGE may Adjusted for age, smoking, hypertension, dyslipidemia, prevalent cardiovascular disease, prevalent diabetes, frailty, BMI/waist, creatinine, vitamin D, and fasting glucose. Data are shown as fold-SD increase in bone turnover marker per 1-SD increase in AGEs and esRAGE (95% CI) and P value.
Abbreviation: CTX, C-terminal cross-linked telopeptide. predispose men to greater deleterious effects of AGEs in bone, acting via RAGE in the absence of the decoy receptor. If circulating esRAGE is reduced in the setting of fasting hyperglycemia, this may increase bone fragility and fracture risk. We found no correlations between CML and the different bone turnover markers. Other assessing associations between AGEs and bone turnover markers have reported inconsistent results. Schwartz et al. (21) demonstrated that markers of bone formation and resorption had small but significant positive associations with pentosidine levels. However, Yamamoto et al. (22) found no correlation between serum pentosidine and bone metabolic markers. Further research is needed to clarify the relationship between AGEs such as CML and bone turnover.
We found evidence of a nonlinear association between CML and incident hip fracture in older men. Men with CML in the third quartile of values had approximately half the risk of hip fracture compared with men with CML in the lowest quartile. The association between AGEs and fracture risk has been studied previously in different subject groups. Neumann et al. (24) demonstrated that high serum pentosidine was associated with prevalent fractures in type 1 diabetes independent of bone mineral density. Schwartz et al. (21) found that pentosidine was associated with fracture risk in older adults with diabetes but not in those without diabetes. Yamamoto et al. (22) demonstrated that serum pentosidine levels were positively associated with vertebral fractures in postmenopausal women with type 2 diabetes, also independent of BMD. Tamaki et al. (25) have shown in a population of older men that increased esRAGE to pentosidine ratio levels were associated with a decreased fracture risk independent of BMD and HbA 1c . Barzilay et al. (26) reported that CML levels were associated with hip fracture risk in older adults independent of BMD and with no difference between patients with and without diabetes. Our findings differ from these studies in identifying a nonlinear or U-shaped association between circulating CML and hip fracture risk. This association was robust after adjustment for potential confounders with a substantial effect size demonstrated by the hazard ratio of 0.49 for men with CML in the third quartile. Our findings are consistent with evidence that the pathogenic effects of AGEs on bone are multifactorial and may cause biomechanical changes, deteriorating bone strength via nonenzymatic cross-linking of collagen without causing cellular dysfunction (3, 12, 41 ). Thus, is it possible that AGEs such as CML may increase bone fragility and fracture risk without altering bone turnover. Our findings support the potential utility of CML as a biomarker for risk of incident hip fracture in older men. However, further studies are needed to clarify why this association is U-shaped rather than linear and determine the optimal range of CML that is associated with the lowest risk of fracture.
The strengths of this study are that we studied a large population of older men with parallel assays of CML, methylglyoxal, glyoxal, and esRAGE to assess the entire pathway of AGEs. We assessed the association with a panel of bone turnover markers and hip fracture risk. Multivariable regression analyses were conducted to assess associations of AGEs and esRAGE with fasting glucose and bone turnover markers, as well as CML with hip fracture, adjusting for age, smoking, hypertension, dyslipidemia, prevalent cardiovascular disease, prevalent diabetes, frailty, BMI/waist, creatinine, and vitamin D. This study has several limitations. We analyzed a single blood sample at baseline and did not have serial data, and only a random subset of participants had assays for glyoxal, methylglyoxal, and esRAGE. Although no associations were seen for glyoxal and methylglyoxal, the results for esRAGE were informative. Analyses were adjusted for age, and thus the associations are less likely to represent confounding from this source. However, the cohort comprises older men, and the results may not apply to younger men. HbA 1c was not analyzed in this cohort. We analyzed fasting glucose levels, which may be a less accurate marker of glycemic control and severity of disease. WADLS captures data for incident hip fractures, as men with hip fractures almost invariably present to the hospital. We did not analyze vertebral fractures as WADLS does not comprehensively capture these events given that a proportion of men with vertebral fractures are managed without hospitalization. Nevertheless, hip fractures are the major cause for morbidity in older men. As this was an observational study, we are unable to prove causation. Finally, we cannot make any comment on associations in women.
In conclusion, there appears to be a complex interaction between glycemia, AGEs, esRAGE, and bone such that AGEs and esRAGE are associated with hyperglycemia in reciprocal fashion, esRAGE with bone formation, and CML with fracture risk in older men. Further studies are needed to assess whether CML could be used to improve risk stratification for hip fracture in older men and to test whether improving glycemic control in men with diabetes would modulate AGEs and esRAGE and possibly reduce fracture risk. Cox proportional hazards regression with the outcome of incident hip fracture according to CML in quartiles. Data are hazard ratios (95% CIs) and P values, unadjusted and adjusted for age, smoking, hypertension, dyslipidemia, prevalent cardiovascular disease, prevalent diabetes, frailty, BMI/waist, creatinine, vitamin D, and fasting glucose.
Abbreviation: Q, quartile.
